Juniper Publishers-Medical Imaging in Novel Drug Development

Juniper Publishers-Open Access Journal of Cancer


Authored by Sunil Aggarwal

Medical Imaging is now being used extensively, in fact more than ever, for clinical trials for a new drug development. Medical imaging can be used through any of the available imaging modalities, including quantitative imaging with the help of CT, MRI or hybrid PET-CT. Much time and money can be saved in not proceeding with a clinical trial as imaging can predict fairly well and early about the efficacy of a compound for the disease process in its evaluation as a “Go-No Go” approach.
FDA and other regulatory authorities also believe that medical imaging is a critical component in its Critical Path Opportunity List of 2006. It is significant to note that pharmaceutical companies and CROs employ imaging as its important tool to quantify matrix for its justification of introducing a new drug, but standardization in terms of patient positioning or the central reads have to be justified against institutional reads.

For more open access journal in juniper publishers click on: https://juniperpublishers.com/index.php
For more articles in Peer reviewed Journal of Cancer Therapy and Oncology click on:  https://juniperpublishers.com/ctoij/index.php

Comments

Popular posts from this blog

Drivers of Precision Medicine: Liquid Biopsy and Next-Generation Sequencing

Recent Advance in Diagnosis, Pathogenesis and Risk Stratification of Essential Thrombocythemia

A Young Woman with Coomb's Positive Severe Haemolytic Anaemia and Hodgkin Lymphoma that Responded Completely to Rituximab: A Case Report